Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.
View Top Employees from Pacylex Pharmaceuticals, Inc.Website | http://www.pacylex.com |
Revenue | $5 million |
Employees | 10 (2 on RocketReach) |
Founded | 2012 |
Address | 10180 101 Street, #2600, Edmonton, Alberta T5J 3Y2, CA |
Phone | (780) 264-4295 |
Technologies |
JavaScript,
HTML,
Twitter
+10 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Health Diagnostics, Health Care, Life Science, Medical, Pharmaceutical, Therapeutics |
Competitors | BRI Biopharmaceutical Research Inc., Biomolecules For Life Inc., ChemRoutes Corporation, Monogenic Pharmaceuticals |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Pacylex Pharmaceuticals, Inc. employee's phone or email?
The Pacylex Pharmaceuticals, Inc. annual revenue was $5 million in 2024.
Ryan Heit is the Co-Founder and Vice President of Operations of Pacylex Pharmaceuticals, Inc..
2 people are employed at Pacylex Pharmaceuticals, Inc..
Pacylex Pharmaceuticals, Inc. is based in Edmonton, Alberta.
The NAICS codes for Pacylex Pharmaceuticals, Inc. are [3254, 32541, 325, 32].
The SIC codes for Pacylex Pharmaceuticals, Inc. are [283, 28].